论文部分内容阅读
目的探讨mi R-150再表达通过靶向c-Myb诱导EBV阳性Burkitt淋巴瘤的分化机制。方法使用再表达后的mi R-150基因,分别对EBV阳性和EBV阴性的Burkitt淋巴瘤进行分化诱导,并利用流式细胞技术,对比分析分化后细胞的免疫表型及细胞大小。结果流式细胞技术分析结果中,EBV阳性细胞群中CD19蛋白中的荧光蛋白比例及mi R-150比例均明显低于EBV阴性细胞群,且EBV阳性组的细胞大小及细胞器数量较EBV阴性组均明显增多,组间分析结果的差异有统计学意义(P<0.05)。结论 mi R-150的再表达可通过靶向诱导c-Myb的表达,使EBV阳性Burkitt淋巴瘤向正常细胞分化,具有较高的治疗应用价值。
OBJECTIVE: To investigate the differentiating mechanism of mi R-150 re-expression in EBV-positive Burkitt’s lymphoma by targeting c-Myb. Methods The re-expressed mi R-150 gene was used to differentiate into EBV-positive and EBV-negative Burkitt’s lymphoma. The immunophenotype and cell size of the differentiated cells were analyzed by flow cytometry. Results In the results of flow cytometry analysis, the percentage of CD19 protein in the EBV-positive cell population and the ratio of mi R-150 were significantly lower than those in the EBV-negative cell population, and the cell size and the number of organelles in the EBV-positive group were lower than those in the EBV-negative group Were significantly increased, the results of the analysis of the differences between groups were statistically significant (P <0.05). Conclusion The re-expression of mi R-150 can induce EBV-positive Burkitt lymphoma to differentiate into normal cells by targeting the expression of c-Myb, which is of high therapeutic value.